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Abstract 
 
Objective(s) 
Recent studies on human indicate that the introduction of therapeutic use of tolerogenic dendritic cell (DC) 
for chronic inflammatory conditions is imminent. For the purpose of defining CGRP potency in tolerogenic 
DC production, we investigated the phenotype and IL-12 production of DCs generated from the monocytes 
of rheumatoid arthritis (RA) patients in the presence of the calcitonin gene-related peptide (CGRP), as a 
multifunctional neuropeptide. 
Materials and Methods 
DCs were generated from isolated monocytes from four resistant and two early female RA patients using IL-
4, GM-CSF, and CGRP at concentrations of 0, 1, and 100 nM. Then, the phenotype of neuropeptide-treated 
or untreated DCs was determined using flow cytometry and the IL-12 production was measured by ELISA. 
Results 
Our study showed that, on the last day of the culture, at a concentration of 1 nM CGRP, the mean 
fluorescence intensity (MFI) for CD80 increased (14.13%) and the MFIs for CD83, CD86, and HLA-DR 
decreased (14.57%, 5.28%, and 6.88% respectively). Moreover, at 100 nM CGRP concentration, the MFI for 
CD80 increased (11.10%) and the MFIs for CD83, CD86, and HLA-DR decreased (4.27%, 18.60%, and 
19.75% respectively). In addition, our results indicated that the mean concentrations of IL-12 produced at 0, 
1, and 100 nm CGRP concentrations measured 13.72±2.41, 11.01±1.61, and 7±1.34 pg/ml respectively.  
Conclusion 
Decreased CD83, CD86, and HLA-DR expression and reduced IL-12 production by CGRP were found in the 
RA patients' monocyte-derived DCs. CD83 is a well-defined DC activation marker. HLA-DR and CD86 are 
appropriate molecules for inducing an immune response.  IL-12 promotes cell-mediated immunity. Therefore 
we suggest that CGRP may be used as an inducer in the production of tolerogenic DCs. 
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Introduction 
Rheumatoid arthritis (RA) is a common 
chronic and progressive autoimmune disease. 
Joint destruction and functional disability in 
RA incurs substantial direct and indirect 
financial costs for patients, their families and 
society (1). Dendritic cell (DC) contributes to 
the initiation, induction, maintenance, and 
complications of RA (2). DC dependent 
autoreactive CD4
+ T cell activation has been 
accepted as one of the central events in RA 
pathogenesis (3). Although many advances 
have been achieved in RA treatment, 
developing more efficient therapeutic methods 
with less side effects remains an area of 
ongoing research (4, 5).  
Dendritic cells (DCs) are the professional 
antigen presenting cells for immune response 
initiation and effector/memory lymphocyte 
production (6). On the other hand, they are 
also known as the potent regulators of 
immune/inflammatory reactions and can 
modulate the effector functions of 
lymphocytes (7). The latter property is 
dependent on various factors, the most 
important of which appears to be the stage of 
their differentiation, activation,  and 
maturation (8). Recent data have shown that 
immature, semi- or partially mature, and 
maturation-resistant (alternatively activated) 
DCs can regulate autoreactive or alloreactive T 
cell responses and promote or restore tolerance 
(8, 9). In other words, DC tolerogenicity is not 
restricted to a specific state or a specific subset 
of these cells (10). Tolerogenic DCs are 
deficient  in  costimulatory  molecule            
(CD80, CD86) expression. Moreover, these 
DCs produce low levels of IL-12p70, high 
levels of IL-10 and indoleamine 2,3- 
dioxygenase (IDO), and are resistant to 
maturation-inducing factors (8, 10). These 
regulatory subsets of DCs are able to acquire 
and present antigen to antigen-specific T cells, 
but fail to deliver adequate co-stimulatory 
signals for the activation or proliferation of T 
cells. Tolerogenic DCs can induce 
anergy/apoptosis in T cells or promote 
regulatory  T  cell  generation/proliferation           
(8, 10). The effective therapeutic application 
of tolerogenic DCs in animal models of 
autoimmune diseases, such as collagen-
induced arthritis, has been previously 
presented (8). Additionally, clinical trials for 
treating rheumatoid arthritis and new-onset 
diabetes are underway (8).            
Neurotransmitters, along with hormones and 
cytokines, mediate a complex network 
between neuro-endocrine-immune systems 
(11). The calcitonin gene- related peptide 
(CGRP), a 37 amino acid neuropeptide, is 
mainly produced by unmyelinated 
postganglionic C-fibers (12, 13). These 
sensory nerves exist in many tissues, such as 
blood vessels, the heart, the kidney, the 
gastrointestinal tract, and lymphoid organs 
(13). T cells, B cells, mast cells and nerve 
growth factor stimulated monocytes also 
secrete CGRP (12-15). CGRP participates in 
the neuro-immune regulatory network. CGRP 
can modulate neutrophil (14), 
monocyte/macrophage (16-18), DC (13, 17, 
19, 20), T cell (21, 22), B cell (23), mast cell 
(24) and eosinophil (25) functions. CGRP 
inhibits neutrophil recruitment and lowers 
TNF production by macrophages, and 
therefore, suppressing acute local and systemic 
inflammation (14). Antigen presentation, 
costimulatory molecule expression, and IL-1 
and IL-12 production are reduced while IL-10 
is increased in Langerhans cells, macrophages 
and DCs exposed to CGRP (13, 16-20). 
Moreover, successful experimental therapeutic 
applications of this neuropeptide for some 
inflammatory disorders have also been 
observed (26, 27). In contrast, some other 
investigations have shown promoting   
inflammatory effects of CGRP, for instance 
rise in IL-6 production (28), the enhancement 
of nitric oxide release and inducible nitric 
oxide synthase activity in LPS-stimulated 
mouse peritoneal macrophages (29), or an 
augmentation of proinflammatory cytokine 
production (TNF, IL-1) in virus infected 
macrophages (30). This study was designed to 
evaluate CGRP's ability to induce tolerogenic 
phenotype and to reduce IL-12 production in 
DCs derived from RA patients. This is the first 
step of a new therapeutic approach that may be 
applicable to many other similar autoimmune 
and inflammatory diseases.     
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Materials and Methods 
Patients 
Studied participants were composed of six 
females who had been diagnosed with RA 
according to the American College of 
Rheumatology’s (ACR) revised criteria. Of 
these patients, the disease had remained 
resistant to treatment (four patients) or was in 
its early state (two patients). The duration of 
the disease in resistant patients was at least 
two years and they were defined by: 1) 
insufficient response to an optimal dose of 
three or four disease modifying anti-
rheumatoid drugs (DMARDs) including 
methotrexate (maximum dose: 25 mg/week) 
for at least three months, 2) positive result for 
the rheumatoid factor (RF), 3) Lack of low 
disease activity according to Disease Activity 
Score 28 (DAS 28 > 3.2). Stable low dose 
prednisone therapy (<10 mg/day) and 
nonsteroidal anti-inflammatory drug (NSAID) 
treatment were allowed. None of them had 
used biologic agents during their course of 
treatment. Early RA patients were diagnosed, 
at most, one month before inclusion and had 
received no steroid therapy.  Early patients 
negative for anti-cyclic citrullinated protein 
antibodies were excluded. The study protocol 
was approved by the Medical Ethics 
Committee of Mashhad University of Medical 
Sciences. Written informed consents were 
obtained from all participants. 
 
Generation and culture of monocyte derived 
dendritic cells 
Monocyte-derived DCs were generated as 
previously described (19, 31). Briefly, 
mononuclear cells from venous peripheral 
blood (approximately 50 ml) were isolated by 
density gradient centrifugation on ficoll 
(Lympholyte, Cedarlane, Hornby, Ontario, 
Canada). Then, monocytes were negatively 
separated using a magnetic activated cell 
sorting kit (Stemcell Technologies, 
Vancouver, British Columbia, Canada). This 
method routinely resulted in more than 80% 
purity, as assessed by flow cytometry. Isolated 
monocytes from each patient were cultured for 
six days at 37 °C in 5% CO2 in an incubator at 
2х10
5 cells/ml in 24 well plates in a volume of 
1 ml RPMI 1640 (Biosera, Ringmer, East 
Sussex, UK) supplemented with 10% FBS 
(Gibco/Invitrogen, Burlington, Canada), 2 mM 
L-gl utamin (Gibco/Invitrogen, Burlington, 
Canada), 50 µM 2-ME (Gibco/Invitrogen, 
Burlington, Canada), 100 U/ml penicillin and 
100 µg/ml streptomycin. Recombinant human 
GM-CSF and IL-4 (R&D Systems, 
Minneapolis, MN) were added at 800 U/ml 
and 500 U/ml, respectively. After three days, 
half of the medium was removed and replaced 
with the same volume of fresh medium 
containing cytokines. For maturity induction,  
1 µg/ml lipopolysaccharide (LPS) (Sigma-
Aldrich, Saint Louis, M) was added on day 6, 
and the culture continued for two more days. 
 
Neuropeptide treatment 
After six days culture in the presence of IL-4 
(500 U/ml) and GM-CSF (800 U/ml),   
immature DCs were exposed to human CGRP 
(Sigma-Aldrich, Saint Louis, MI)  for two 
hours at 37 °C in a CO2 incubator. Based on 
previous studies, we applied two CGRP 
concentrations: 1 and 100 nM. Then, the cells 
were cultured for two additional days in the 
above mentioned medium supplemented with 
LPS (1 µg/ml) and the same concentrations of 
CGRP. 
 
Immunofluorescence labeling and flow 
cytometry 
Monocytes and mature DCs (treated and 
untreated with CGRP) were studied for surface 
markers: CD14, CD11c, CD80, CD83, CD86, 
and HLA-DR on days 1 and 8. Briefly, the 
cells were washed in PBS/BSA. The washed 
cells were then incubated with conjugated 
monoclonal antibodies (Serotec, Oxford, UK) 
for 20 minutes at 4 °C, washed in PBS/BSA, 
and fixed in 1% paraformaldehyde for analysis 
using a FACSCalibur flow cytometer (Becton-
Dickinson, San Jose, CA). Isotype-matched 
conjugated antibodies were used as controls 
for nonspecific bindings. 
 
Cytokine determination by ELISA  
The IL-12 concentration in the supernatants of 
CGRP treated and untreated-cells harvested on 
day 8 was determined, according to the  
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manufacturer's instructions, by an ELISA kit 
purchased from Bender MedSystems (Vienna, 
Austria). The minimal sensitivity of the 
ELISA for human IL-12 was 2.1 pg/ml.   
 
Statistical analysis 
Univariate general linear model, independent 
sample t test, and the Mann-Whitney U test 
were used, as appropriate, for the comparison 
of the samples’ mean values. Results were 
expressed as mean±SEM. A P value less than 
0.05 was judged to be statistically significant.    
 
Results 
Decreasing CD14 and increasing CD11c 
positive cells were clearly observed 
On day 1, in comparison to day 8 of the 
culture, the percentages of CD11c positive 
cells were significantly enhanced and CD14 
positive cells percentages significantly reduced 
(P= 0.000) (Figure 1). On day 1, the mean 
percentages of CD14 and CD11c positive cells 
were 87.84±4.45% and 0.44±0.16% 
respectively. The mean percentages of CD14 
positive cells on day 8 were 2.49±0.81%, 
2.28±0.71%, and 1.46±0.53% at 0, 1 nM, and 
100 nM CGRP concentrations, respectively. 
Also, CD11c mean percentages at 0, 1 nM, 
and 100 nM CGRP concentrations changed to 
84.88±2.28%, 80.15±6.12%, and 82.05±2.96%, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Confidence interval (%95) error bars for the 
percentage of CD14 (A) and CD11c (B) positive cells in 
the beginning (1
st day) and at the end (8
th day) of culture 
in untreated and CGRP treated groups. Monocytes were 
isolated from peripheral blood of patients (n= 6) and 
cultured in the presence of GM-CSF and IL-4 for 8 
days. LPS and CGRP were added on day 6. CGRP was 
applied at concentrations of 0, 1 and 100 nM.    
The expression of CD80, CD83, CD86, and 
HLA-DR increased during the culture period 
The mean fluorescence intensity (MFI) for 
CD80, CD83, CD86, and HLA-DR was 
determined on days 1 and 8 (Table 1). These 
values represented the increase in the 
expression of all makers in both control and 
treated groups on day 8, in comparison to that 
of primary monocytes. Although the elevation 
of CD80, CD86, and HLA-DR expression was 
significant, the increased expression of CD83 
did not show any statistical significance 
(Figure 2 and Table 1).  
 
CGRP did not reduce CD80 expression in 
generated DCs from RA patients    
On day 8, the expression of CD80 did not 
decrease in CGRP-treated DCs in comparison to 
untreated cells (Figures 3 and 4). In early 
specimens, the MFI means for CD80 increased 
by 6.95% and 0.78% at 1 nM and 100 nM 
CGRP concentrations respectively. The resistant 
sample values were determined as 28.74% and 
33.76% at 1 nM and 100 nM concentrations of 
CGRP respectively. In comparison to untreated 
cells, these observed elevations were not 
significant for any CGRP concentration. 
 
 
 
Figure 2. Confidence interval (%95) error bars for MFI 
of CD80 (A), CD83 (B), CD86 (C) and HLA-DR (D) on 
days 1 and 8 at CGRP concentrations of 0, 1 and 100 
nM. Monocytes were isolated from peripheral blood of 
patients (n= 6) and cultured in the presence of cytokines 
(GM-CSF and IL-4) for 8 days. LPS and CGRP were 
added on day 6.      
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Table 1.  Expression of cell surface markers at different concentrations of CGRP on days 1 and 8. 
MF1±SEM
a   
P value   
8
th day   1
st day  
CGRP Concentration (nM)      Marker  
0.005   59.29±8.18  0  
0.005   72.14±12.05  1  
0.019   72.94±16.22 
19.15±6.53 
100  
 
CD80   
 
0.121   103.42±16.82  0  
0.275   85.60±8.38  1   
0.127   97.04±12.03 
57.17±21.70 
100  
CD83  
0.000    384.09±26.51  0  
0.000    365.50±24.79  1  
0.000    349.92±26.07 
19.17±5.59 
100  
CD86  
0.011   2475.83±585.90  0  
0.001   2078.01±368.44  1   
0.003   2166.68±365.38 
188.95±47.92 
100   
HLA-DR   
 
Abbreviations: CGRP, calcitonin gene related peptide; MFI, mean fluorescence intensity; SEM, standard error of the mean. 
a For each concentration of CGRP the mean of detected MFIs for all specimens (early and resistant collectively) are shown. 
 
 
CD83 and CD86 expression were reduced in 
resistant and early RA patients  
In CGRP-treated monocyte-derived DCs, the 
MFI of CD83 decreased at the CGRP 
concentration of 1 nM in both early (14.83%) 
and resistant (18.57%) patients, when 
compared to their controls (without CGRP) on 
day 8. At a concentration of 100 nM CGRP, 
this effect was lower (8.51% and 4.82% for 
early and resistant specimens respectively) 
(Figures 3 and 4). 
In comparison to untreated DCs on day 8, all 
treated DCs showed lowered CD86 expression 
(8.27% and 2.92% at 1 nM and 3.91% and 
11.68% at 100 nM concentrations of CGRP in 
early and resistant samples respectively) 
(Figures 3 and 5). The reducing effects on CD83 
or CD86 were not statistically significant.  
 
HLA-DR expression state was different 
between early and resistant RA patients  
In comparison to the controls on day 8, HLA-
DR expression reduced in the treated DCs 
obtained from early RA cases, at both 1 nM 
(32.17%) and 100 nM (31.96%) CGRP 
concentrations (Figure 5). On the other hand, 
the expression of HLA-DR did not decrease in 
resistant specimens and showed little increase, 
in comparison to the controls on day 8 (2.03% 
and 9.40% at 1 nM and 100 nM CGRP 
concentrations respectively) (Figure 5).  
 
IL-12 production was reduced in CGRP 
treated DCs  
IL-12 measurement after LPS stimulation 
demonstrated that CGRP treated cells, in both 
early and resistant patients, produce lower levels 
of this cytokine (Figure 6). The means of IL-12 
production at 0, 1, and 100 nM concentrations of 
CGRP were 14.15±3.94, 12.81±0.08, and 
8.28±2.28 pg/ml in early and 13.29±4.36, 
9.22±3.02 (P= 0.051), and 5.73±1.53 pg/ml in 
resistant patients respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. IL-12 production by dendritic cells treated with CGRP, (A) in all patients (early and resistant, collectively) 
and (B) in two groups of patients (early and resistrant, separately), was altered. Supernatants were harvested on day 8 
and IL-12 levels were measured by sandwich ELISA. For DC maturation LPS was applied on day 6. (P= 0.051)   
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Figure 3. Alterations of cell surface markers expression 
in generated dendritic cells from monocytes of 
rheumatoid arthritis patients on day 8 at applied CGRP 
concentrations. Monocytes were isolated from 
peripheral blood mononeuclear cells of rheumatoid 
arthritis patients (early and resistant) and cultured in the 
presence of GM-CSF and IL-4 for 8 days. LPS and 
CGRP were added on day 6. CGRP was applied at 
concentrations of 0, 1 and 100 nM.  
 
 
 
 
Figure 4. Alterations of CD80 and CD83 expression in 
generated dendritic cells from monocytes of early and 
resistant rheumatoid arthritis patients on day 8 at 
applied CGRP concentrations. Monocytes were isolated 
from peripheral blood mononeuclear cells of patients 
and cultured in the presence of GM-CSF and IL-4 for 8 
days. LPS and CGRP were added on day 6. CGRP was 
applied at concentrations of 0, 1 and 100 nM.  
 
 
 
Figure 5. Alterations of CD86 and HLA-DR expression 
in generated dendritic cells from monocytes of early and 
resistant rheumatoid arthritis patients on day 8 at 
applied CGRP concentrations. Monocytes were isolated 
from peripheral blood mononeuclear cells of patients 
and cultured in the presence of GM-CSF and IL-4 for 8 
days. LPS and CGRP were added on day 6. CGRP was 
applied at concentrations of 0, 1 and 100 nM.  
 
Discussion 
Bidirectional communication between the 
neuroendocrine and immune systems provides a 
finely tuned regulatory network that is necessary 
for health (11). In many inflammatory, 
infectious or autoimmune diseases, we can see 
disturbances at any level of these intimate 
interactions (32, 33). CGRP, as a neuropeptide, 
is a shared ligand in neuroendocrine and 
immune systems (34). Many investigators have 
shown the inflammatory and modulatory effects 
of this sensory neuropeptide on immune cells 
(14, 16, 29, 30, 35). In this study, the CGRP 
tolergenic effects on DCs derived from RA 
patients was evaluated.  
Our results showed both the CGRP-treated 
cells and the controls differentiate to DCs. 
CD11c positive cells significantly increased 
whereas CD14 positive cells significantly 
decreased. Also, except for CD83, the 
expressions of other markers (CD80, CD86, 
and HLA-DR) significantly enhanced at the 
end of the culture. Non-significant 
enhancement of CD83 may be correlated to  
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the increased expression of this molecule in 
patients' monocytes. It is known that CD83 is 
pre-formed inside monocytes and rapidly 
expressed on the cell surface upon activation 
(36). Additionally, TNF is recognized as an 
inducer for the human CD83 promoter (37). 
Therefore, it can be postulated that the 
inflammatory environment and high 
production of TNF in RA patients results in 
monocyte activation and the elevation of 
CD83 expression.        
From a narrower perspective, at a 
concentration of 1 nM CGRP, the expression 
of CD83 decreased in comparison to the 
controls. Although CD83 has long been known 
as one of the best markers for the evaluation of 
dendritic cell maturity (37), only a few studies 
have explored the effect of CGRP on the 
expression of CD83 in human DCs. Carucci           
et al (19) showed that the DC expression of 
CD83 was left unchanged by CGRP treatment. 
It should be noted that their study was 
performed at a 100 nM concentration of CGRP 
and on normal human monocytes. On the other 
hand, we applied two different CGRP 
concentrations on DCs derived from RA 
patients.  
In the present study, as in other similar 
works (16, 17, 19), CD80 (B7-1) expression 
increased and the expression of CD86 (B7-2) 
reduced in comparison to that of the controls. 
There are growing evidences that CD80 and 
CD86 molecules have distinct functional 
properties, in addition to dissimilar structural 
features (38-41). These two molecules have 
different affinities for their ligands, CD28 and 
CD152 (CTLA-4). CD80 interactions favor 
CD152 and it can be assumed that CD80 is the 
major ligand for this molecule. In contrast, 
CD86 interactions are biased toward CD28. 
B7-1 and B7-2 have distinct effects on B (42), 
T, and regulatory T cells. CD86
-/- as apposed 
to CD80
-/- DCs could promote TGF-β, IL-10 
producing regulatory T cells in vivo (39). 
Moreover, another study has shown that 
CTLA-4, the major CD80 ligand, plays a 
critical role in Foxp3 regulatory T cell 
functions (40). Similar evidences have also 
been observed in T cell activation (41). Thus, 
it may be assumed that CD80/CD86 are not 
interchangeable costimulators. Our finding 
that CGRP increases CD80 and decreases 
CD86 expression in DCs in fact supports this 
theory. This whole process leads to the down 
regulation of immune responses which is the 
desired outcome of tolerance induction. 
In this study, HLA-DR expression exhibited 
different behavior in early and resistant 
patients. As in other similar studies (19, 20), 
HLA-DR decreased in the early cases of RA 
compared to the controls. However, in 
resistant patients, HLA-DR did not decrease in 
treated specimens when compared to the 
controls. It is obvious that HLA-DR reduction, 
as an antigen presenting molecule, can 
modulate T cell activation and, therefore, 
control immune reactions. The inability of 
CGRP to decrease HLA-DR in dendritic cells 
derived from resistant RA patients could be 
pertinent to disease progression and associated 
long term alterations in factors related to cell 
environmen, particularly cytokines. The 
various effects of medical treatment should 
also be considered. It should not be overlooked 
that even this situation might be helpful in 
tolerance induction. An increased antigen 
presentation in the absence of appropriate 
costimulation (CD86) may lead to the 
unresponsiveness of T cells.  
The CGRP-mediated suppression of IL-12 
has been demonstrated by previous similar 
studies (15-17). The reduced production of IL-
12 along with the decreased expression of 
costimulatory molecules are considered to be 
important characteristics of tolerogenic DCs 
(43). Upon maturation, DCs produce high 
levels of IL-12, an essential CD4
+ T helper 1 
cell-deriving cytokine which promotes 
inflammatory responses. DC resistance to 
maturation is necessary for the exhibition of its 
tolerogenic properties (8, 37).      
Less attention has been paid to the 
neuroimmunoendocrine aspects of RA 
pathogenesis. Patients with RA show multiple 
alterations in the endocrine and nervous 
systems (including CGRP). Both potentially 
affect different features of the immune system 
and, therefore, the final disease manifestations 
(44). The better understanding of complex 
neuroimmune interactions could lead to  
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finding novel therapeutic targets for the 
treatment of many progressive and debilitative 
inflammatory conditions. 
 
Conclusion 
This study demonstrates, for the first time, that 
CGRP can decrease CD83, CD86, HLA-DR 
expression, increase CD80 expression and 
reduce IL-12 production in DCs generated 
from RA patients' monocytes. These findings 
indicate that the ability of CGRP to skew in 
vitro generated DCs toward a tolerogenic 
profile in RA patients. Therefore, we suggest 
that CGRP may be applicable in the 
production of tolerogenic DCs in these 
patients. Further studies are needed to clarify 
the effects of this neuropeptide on patients' 
monocyte-derived DC functions.   
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